In 2022, Cancer52 and the National Cancer Research Institute (NCRI) joined forces to create a report titled: Research into rare and less common cancers: An analysis of research spend by Cancer52 members and NCRI partners.
The report is in a digital format and can be accessed online. It provides a snapshot of non-industry research spend on rare and less common cancers, separate to the spend on the four most common cancers, lung, breast, bowel and prostate.
The analysis covers how spend on rare and less common cancers differs to spend on common cancers in terms of research area, and compares research spend on cancer type to mortality.
Top ten rare and less common cancers by mortality compared to research spend
The report looks at patterns in regional spend within the UK, as well as at the effect of the COVID-19 pandemic during the financial year 2020-2021.
Combined spend (Cancer52 members and NCRI Partners) by region
As you may have seen, the NCRI have recently announced its decision to wind down the organisation but have approved its release as the wind down does not affect the validity of the report.